Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
British Journal of Cancer, 05/18/2012
Clinical Article
Kususda Y et al. – Combined use with OGX–011 may be useful in enhancing the cytotoxic effect of sorafenib on renal cell carcinoma (RCC) by inducing apoptosis and inactivating major signal transduction pathways.



